(Q37514235)

20 August 2017

1 reference

title

HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspects (English)

1 reference

20 August 2017

1 reference

David Nolan

1

1 reference

20 August 2017

publication date

1 January 2009

1 reference

Critical Reviews in Clinical Laboratory Sciences

20 August 2017

published in

1 reference

20 August 2017

volume

46

1 reference

20 August 2017

issue

3

1 reference

20 August 2017

page(s)

153-165

1 reference

Pharmacogenomics: translating functional genomics into rational therapeutics

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

Pharmacogenetics and the practice of medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

Medical genetics: a marker for Stevens-Johnson syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

Abacavir plus lamivudine: a review of their combined use in the management of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

The metabolic activation of abacavir by human liver cytosol and expressed human alcohol dehydrogenase isozymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

Cutaneous metabolism of glycol ethers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

Immune responses to abacavir in antigen-presenting cells from hypersensitive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

Reasons for Early Abacavir Discontinuation in HIV-Infected Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

Immune restoration disease after antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

Drug hypersensitivity in HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

Clinical and immunogenetic correlates of abacavir hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

Hypersensitivity related to abacavir in two members of a family

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

HLA-B*5701 screening for hypersensitivity to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

HLA-B*5701 typing by sequence-specific amplification: validation and comparison with sequence-based typing

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

HLA-B*27 typing by sequence specific amplification without DNA extraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

A whole-genome association study of major determinants for host control of HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

Polymorphisms at position 245 of HIV reverse transcriptase do not accurately predict the presence of human leukocyte antigen B*5701.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

Cellular mechanisms of T cell mediated drug hypersensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

Potential roles of protein oxidation and the immunoproteasome in MHC class I antigen presentation: the 'PrOxI' hypothesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

Individualising HIV treatment--pharmacogenetics and immunogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

Components of the ligand for a Ni++ reactive human T cell clone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

HLA-DPB1 glutamate 69: a genetic marker of beryllium disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

Pharmacogenetics in drug regulation: promise, potential and pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

The danger model: a renewed sense of self

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

A Simple Screening Approach to Reduce B*5701-Associated Abacavir Hypersensitivity on the Basis of Sequence Variation in HIV Reverse Transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937817

10.1080/10408360902937817

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference